{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:40:50Z","timestamp":1791499250872,"version":"4.3.4"},"reference-count":0,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T00:00:00Z","timestamp":1507075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T00:00:00Z","timestamp":1507075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfus Med Hemother"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>&lt;b&gt;Background: &lt;\/b&gt;Cytomegalovirus(CMV)-related diseases are a serious cause of morbidity and mortality following hematopoietic stem cell transplantation (HSCT). CMV-specific cytotoxic T lymphocytes (CMV-CTLs) have been reported as an alternative to antiviral drugs that provide long-term CMV-specific immunity without major side effects. However, their application has been limited by the prolonged manufacturing process required. &lt;b&gt;Methods:&lt;\/b&gt; In this study, we applied the IFN-&amp;#x03B3; cytokine capture system (CCS) using the fully automated CliniMACS Prodigy device for rapid production of CMV-CTLs, which may be applicable in clinically urgent CMV-related diseases. Five validation runs were performed using apheresis samples from randomly selected CMV-seropositive healthy blood donors. Successive processes, including antigen stimulation, anti-IFN-&amp;#x03B3; labeling, magnetic enrichment and elution, were then performed automatically using the CliniMACS Prodigy, which took approximately 13 h. &lt;b&gt;Results:&lt;\/b&gt; The original apheresis samples consisted mainly of CD45RA+ CD62L+ na\u00efve T cells as well as 0.3% IFN-&amp;#x03B3;-secreting CD3+ T cells that showed a response to the CMV pp65 antigen (CD3+ IFN-&amp;#x03B3;+ cells). Following IFN-&amp;#x03B3; enrichment, the target fraction contained 51.3% CD3+ IFN-&amp;#x03B3;+ cells with a reduction in na\u00efve T cells and selection of CD45RA- CD62L- and CD45RA+ CD62L- memory T cells. Furthermore, extended culture of these isolated cells revealed functional activity, including efficient proliferation, sustained antigen-specific IFN-&amp;#x03B3; secretion, and cytotoxicity against pp65-pulsed target cells. &lt;b&gt;Conclusion:&lt;\/b&gt; The findings reported here suggest that the IFN-&amp;#x03B3; CCS by the CliniMACS Prodigy is a simple and robust approach to produce CMV-CTLs, which may be applicable for the treatment of clinically urgent CMV-related diseases.<\/jats:p>","DOI":"10.1159\/000479238","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T07:30:27Z","timestamp":1507620627000},"page":"13-22","source":"Crossref","is-referenced-by-count":16,"title":["Robust Production of Cytomegalovirus pp65-Specific T Cells Using a Fully Automated IFN-&amp;#x03B3; Cytokine Capture System"],"prefix":"10.1159","volume":"45","author":[{"given":"Nayoun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Sun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keon-Il","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Yeon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunejin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2017,10,4]]},"container-title":["Transfusion Medicine and Hemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/479238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/479238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:43:30Z","timestamp":1745426610000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000479238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,4]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,30]]}},"URL":"https:\/\/doi.org\/10.1159\/000479238","archive":["Portico"],"relation":{},"ISSN":["1660-3796","1660-3818"],"issn-type":[{"value":"1660-3796","type":"print"},{"value":"1660-3818","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,4]]}}}